Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice.

摘要: ○ Context.-Practicing pathologists often encounter controversial clinical issues and nonstandardized laboratory approaches to the evolving science of predictive/prognostic tumor marker assays. This dilemma becomes especially acute when assay is sole determinant for selection a specific therapy. Objectives.-To summarize areas practical agreement identify opportunities improvement in Her2/neu testing breast cancer. Design.-The College American Pathologists created new comprehensive education model, called Strategic Science, with expert speakers integrating basic, clinical, scientific Her-2/neu aspects management. Setting.-Symposium held May 4 5, 2002, Rosemont, III. Participants.-Ten more than 100 attendees. Results.-components addressed were technology assessment, practice guidelines, quality assurance, regulatory compliance, risk liability, billing coding, cost analysis, consultation, information management, results reporting. Conclusions.-This Science symposium derived agreement, defined current state-of-the-art, identified testing.